Cathie's Ark LogoCathie's Ark
Trading Floor Community IconFrom the Trading Floor:
Fate Therapeutics Inc Logo

ARKK Holdings of Fate Therapeutics (FATE) - Updated Daily

Lock Icon
Date
Direction
Shares
Fund Weight
Fund
May 11, 2021BUY642100.0241%ARKK
May 10, 2021BUY2041700.0775%ARKK
April 12, 2021BUY1396990.0436%ARKK
April 6, 2021BUY1022690.0342%ARKK
April 5, 2021BUY314230.0109%ARKK

Key Statistics

🕵🏼Found In🏷Last Price
ARKKARKG$86.79
⚖️Weighting🧢Market Cap
1.35%$8.16b
🏋🏿‍♂️Weight Rank In ARKK🧮Price to Sales
26203.72
🏋️‍♀️Weight Rank Across All Funds🐻Short Percent
1918.19
🎫Ark Ownership Percent🌏Country
3.58%🇺🇸United States
Description
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. Fate Therapeutics is headquartered in San Diego, CA.
Website
www.fatetherapeutics.com

Research Notes and Commentary for FATE

January 29, 2021

Ark Trades and Storylines

Trading Floor
Reported excellent Phase 1 clinical trial results for it's experimental CAR-NK therapy on...